These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24462126)

  • 41. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.
    Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G;
    J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?
    Ongaro A; De Mattei M; Pellati A; Caruso A; Ferretti S; Masieri FF; Fotinidi M; Farina I; Trotta F; Padovan M
    Rheumatol Int; 2008 Jul; 28(9):901-8. PubMed ID: 18309487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.
    Pavy S; Toonen EJ; Miceli-Richard C; Barrera P; van Riel PL; Criswell LA; Mariette X; Coenen MJ
    Ann Rheum Dis; 2010 Jun; 69(6):1022-8. PubMed ID: 19966089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
    Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
    Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
    Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
    Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of tumor necrosis factor alpha and its receptor polymorphisms with rheumatoid arthritis in female patients.
    Hussein YM; Mohamed RH; Pasha HF; El-Shahawy EE; Alzahrani SS
    Cell Immunol; 2011; 271(1):192-6. PubMed ID: 21777909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study.
    Cañete JD; Albaladejo C; Hernández MV; Laínez B; Pinto JA; Ramírez J; López-Armada MJ; Rodríguez-Cros JR; Engel P; Blanco FJ; Sanmartí R
    Rheumatology (Oxford); 2011 Apr; 50(4):721-8. PubMed ID: 21134963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
    Segal B; Rhodus NL; Patel K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):778-87. PubMed ID: 18930662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
    Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
    Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
    Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
    de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A
    J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 57. Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort).
    Duquenne C; Wendling D; Sibilia J; Job-Deslandre C; Guillevin L; Benichou J; Flipo RM; Guillemin F; Saraux A
    Clin Exp Rheumatol; 2017; 35(4):638-646. PubMed ID: 28516872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.
    Bowes JD; Potter C; Gibbons LJ; Hyrich K; Plant D; Morgan AW; Wilson AG; Isaacs JD; Worthington J; Barton A;
    Pharmacogenet Genomics; 2009 Apr; 19(4):319-23. PubMed ID: 19262425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs.
    Iannone F; Tampoia M; Giannini M; Lopalco G; Cantarini L; Villalta CD; Galeazzi M; Lapadula G
    Clin Exp Rheumatol; 2016; 34(3):424-9. PubMed ID: 26885600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.